Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid

Bedaquiline (B), pretomanid (Pa) and linezolid (L) are key components of new regimens for treating rifampicin-resistant tuberculosis (TB). However, there is limited information on the global prevalence of resistance to these drugs and the impact of resistance on treatment outcomes. Mycobacterium tub...

Descripción completa

Detalles Bibliográficos
Autores principales: Timm, Juliano, Bateson, Anna, Solanki, Priya, Paleckyte, Ana, Witney, Adam A., Rofael, Sylvia A. D., Fabiane, Stella, Olugbosi, Morounfolu, McHugh, Timothy D., Sun, Eugene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584172/
https://www.ncbi.nlm.nih.gov/pubmed/37851685
http://dx.doi.org/10.1371/journal.pgph.0002283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584172/
https://www.ncbi.nlm.nih.gov/pubmed/37851685
http://dx.doi.org/10.1371/journal.pgph.0002283

Ejemplares similares